The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

Table 5 Model-derived means and tests assessing the changes in hepatic fibrosis: the main effects and interactions

Model	Variable	Pre-HSCT		Post-HSCT		Δ (se)	P value
Model 1: Time	Ferritin	2555.47 (239.82)		1995.70 (239.82)		− 559.77 (339.15)	0.101
	AST	29.06 (1.169)		29.04 (1.169)		−0.02 (1.65)	0.99
	ALT	37.67 (1.58)		40.08 (1.58)		2.41 (2.24)	0.282
	FibroScan score	7.40 (0.38)		9.06 (0.38)		1.66 (0.54)	0.0025
	Hepatic T2* MRI	19.42 (1.31)		17.43 (1.31)		−1.99 (1.85)	0.283
	Liver stage	1.78 (0.11)		1.62 (0.11)		−0.16 (0.15)	0.297
	Liver grade	2.37 (0.13)		2.53 (0.13)		0.15 (0.19)	0.412
	Liver iron dry weight	10.22 (0.71)		8.17 (0.71)		−2.05 (1.01)	0.0442
Model 2: Time*Intervention	Variable	Pre-HSCT		Post-HSCT		Δ (se)	P value
	Variable	Without mesenchyme	With mesenchyme	Without mesenchyme	With mesenchyme	Δ (se)	P value
	Ferritin	2835.04 (405.78)	2404.04 (308.50)	2305.80 (419.24)	1826.65 (296.44)	48.16^a (347.49)	0.89
	AST	29.30 (1.97)	28.90 (1.50)	28.65 (2.03)	29.27 (1.45)	−1.02^a (1.92)	0.596
	ALT	37.41 (2.67)	40.20 (2.74)	37.79 (2.02)	40.02 (1.96)	0.55^a (2.68)	0.837
	FibroScan score	7.46 (0.64)	7.36 (0.49)	9.19 (0.66)	8.99 (0.47)	−0.10^a (0.68)	0.881
	Hepatic T2* MRI	19.55 (2.21)	16.31 (1.67)	21.91 (2.27)	18.04 (1.62)	−0.63^a (2.21)	0.775
	Liver stage	1.98 (0.18)	1.66 (0.14)	1.72 (0.19)	1.56 (0.13)	0.16^a (0.24)	0.518
	Liver grade	2.42 (0.22)	2.34 (0.17)	2.49 (0.23)	2.55 (0.16)	0.14^a (0.36)	0.689
	Liver iron dry weight	8.11 (1.22)	11.37 (0.90)	6.36 (1.23)	9.14 (0.89)	−0.47^a (0.93)	0.613

Mixed-effect linear regression models adjusted for patient’s age, sex matching, ABO matching, source of HSCT, aGvHD, cGvHD, ferritin, and dry iron liver
Se standard error
^aΔD = (post-HSCT-positive mesenchymal − pre-HSCT-positive mesenchymal) − (post-HSCT-negative mesenchymal − pre-HSCT-negative mesenchymal)

ISSN: 1757-6512